Actinogen Medical - A$11.1m capital raise completed
Actinogen Medical announced the successful completion of its A$3.0m share purchase plan (SPP), which closed 1.3x oversubscribed. With its...
165 Views
Actinogen Medical - Funding in place to complete XanaMIA Phase IIb
Actinogen Medical announced a capital increase of up to A$11.1m on 18 September, consisting of the successful completion of an A$8.1m (gross) share...
176 Views
Actinogen Medical - Further positive XanaCIDD results on depression
New data were revealed from Actinogen Medical’s ongoing analysis of the now-completed XanaCIDD study that support the view that the company’s lead...
143 Views
Actinogen Medical - XanaCIDD data narrow the focus in depression
While the results from Actinogen’s XanaCIDD exploratory Phase IIa study in patients with major depressive disorder (MDD) did not meet the primary...
237 Views
Actinogen Medical - Publication of XanADu biomarker analysis
Actinogen Medical announced that the prespecified biomarker subset analyses on stored plasma samples (n=72) from its previous Phase IIa XanADu...
401 Views